A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain | Association for Accessible Medicines
Welcome Message - Blog from AAM President and CEO Dan Leonard: Generics: The Bridge to A Vaccine.

A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain

Introduction

A closely connected, diverse and resilient pharmaceutical supply chain based in the United States and in U.S. allied countries (for example, Canada, Europe, India, Israel and Jordan) is the best means to ensure that U.S. patients and the U.S. health care system have access to a secure and consistent supply of critical pharmaceuticals. The United States already plays an important role in this supply chain, with generic companies providing for more than 36,000 jobs at nearly 150 facilities, and manufacturing more than 70 billion doses of prescription medicines annually.1

With strategic support from the U.S. government, the economic footprint of the generic drug industry in the U.S. can expand even more, leading to increased national security, a reduction of dependence on any one country for key pharmaceuticals or their components, and an expanded employment base.

View Blueprint

Read Blog

View Supply Chain Presentation

 


1. Based on a 2016 survey of Association for Accessible Medicines’ member companies.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.